CCND1 Gene Status in Breast Cancer
Author Information
Author(s): Bièche I, Olivi M, Noguès C, Vidaud M, Lidereau R
Primary Institution: Laboratoire de Génétique Moléculaire–UPRES JE 2195, Université René Descartes–Paris V
Hypothesis
What is the prognostic value of CCND1 gene status in sporadic breast tumors?
Conclusion
CCND1 gene status can predict hormone responsiveness and relapse-free survival in breast cancer patients.
Supporting Evidence
- CCND1 overexpression was observed in 32.8% of breast tumor samples.
- Patients with CCND1-amplified tumors had shorter relapse-free survival compared to those without alterations.
- CCND1 overexpression was significantly correlated with positive estrogen receptor status.
Takeaway
This study looked at a gene called CCND1 in breast cancer to see if it could help doctors understand how patients might respond to treatment.
Methodology
Real-time quantitative PCR and RT–PCR assays were used to measure CCND1 gene expression in breast tumor samples.
Potential Biases
Potential bias in patient selection and treatment history.
Limitations
The study only included unilateral invasive primary breast tumors and may not be generalizable to all breast cancer types.
Participant Demographics
Mean age of participants was 58.3 years, with a range from 34 to 91 years.
Statistical Information
P-Value
0.0003 for CCND1 overexpression correlation with estrogen receptor positivity; 0.011 for relapse-free survival.
Confidence Interval
36.6–89.4 for 5-year RFS of CCND1-amplified tumors.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website